

Special Issue

Epstein-Barr Virus-Associated Cancers: From Pathogenesis to Treatment

Message from the Guest Editors

This Special Issue aims to provide an up-to-date assessment of the current status of our understanding of EBV's contribution to virus-associated lymphomas and carcinomas and how this knowledge impacts the diagnosis and treatment of these cancers. Original research articles and reviews are welcome. Research areas may include (but are not limited to) the following: (i) the role of EBV in the development of different tumours, including the contribution of EBV latent and lytic proteins; (ii) the interaction of different co-factors and how these work in concert with EBV to drive oncogenesis; (iii) the impact of EBV on the tumour microenvironment; (iv) the use of EBV as a biomarker in tumour diagnosis and prognosis; (v) current and future approaches to treating EBV-associated cancers, including immunotherapy and targeting of individual EBV proteins; and (vi) the potential of both prophylactic and therapeutic vaccination.

Guest Editors

Prof. Dr. Kwok-Wai Lo

Department of Anatomical and Cellular Pathology, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China

Prof. Dr. Lawrence S. Young

Warwick Medical School, University of Warwick, Coventry CV4 7AL, UK

Deadline for manuscript submissions

closed (28 February 2023)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/116845

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)